PIV3
MCID: PRN029
MIFTS: 35

Parainfluenza Virus Type 3 (PIV3)

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Parainfluenza Virus Type 3

MalaCards integrated aliases for Parainfluenza Virus Type 3:

Name: Parainfluenza Virus Type 3 53
Human Parainfluenza Virus Type 3 53
Piv3 53

Classifications:



Summaries for Parainfluenza Virus Type 3

NIH Rare Diseases : 53 Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. There is currently no vaccine to protect against parainfluenza virus infections. Most HPIV infections resolve on their own and do not require special treatment, though medical intervention may be necessary for severe breathing problems. Most adults have antibodies against parainfluenza but can get repeat infections.

MalaCards based summary : Parainfluenza Virus Type 3, also known as human parainfluenza virus type 3, is related to newcastle disease and respiratory syncytial virus infectious disease. An important gene associated with Parainfluenza Virus Type 3 is ZNF17 (Zinc Finger Protein 17), and among its related pathways/superpathways are Metabolism of proteins and Transport to the Golgi and subsequent modification. The drugs Glutamic acid and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Parainfluenza Virus Type 3

Diseases related to Parainfluenza Virus Type 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 newcastle disease 29.9 NEU1 IFNB1
2 respiratory syncytial virus infectious disease 29.9 NEU1 IFNB1
3 fetal parainfluenza virus type 3 syndrome 12.5
4 bronchiolitis 10.6
5 vaccinia 10.6
6 measles 10.5
7 polykaryocytosis inducer 10.4
8 croup 10.4
9 stomatitis 10.3
10 meningitis 10.2
11 encephalitis 10.2
12 hypotrichosis and recurrent skin vesicles 10.2
13 viral pneumonia 10.2
14 hydrocephalus 10.2
15 pertussis 10.2
16 bronchopneumonia 10.2
17 diarrhea 10.2
18 lymphopenia 10.2
19 congenital hydrocephalus 10.2
20 hematopoietic stem cell transplantation 10.2
21 medulloblastoma 10.0
22 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
23 proteasome-associated autoinflammatory syndrome 1 10.0
24 legionnaire disease 10.0
25 severe cutaneous adverse reaction 10.0
26 aplastic anemia 10.0
27 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
28 chlamydia pneumonia 10.0
29 erythema multiforme 10.0
30 swine influenza 10.0
31 bone disease 10.0
32 compensatory emphysema 10.0
33 mumps 10.0
34 parotitis 10.0
35 meningoencephalitis 10.0
36 mastitis 10.0
37 respiratory failure 10.0
38 chlamydia 10.0
39 allergic hypersensitivity disease 10.0
40 aseptic meningitis 10.0
41 acute leukemia 10.0
42 guillain-barre syndrome 10.0
43 urethritis 10.0
44 fibrosarcoma 10.0
45 rhinitis 10.0
46 paget's disease of bone 10.0
47 pneumonia 10.0
48 bronchitis 10.0
49 viral encephalitis 10.0
50 influenza 10.0

Graphical network of the top 20 diseases related to Parainfluenza Virus Type 3:



Diseases related to Parainfluenza Virus Type 3

Symptoms & Phenotypes for Parainfluenza Virus Type 3

GenomeRNAi Phenotypes related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.4 ARCN1 COPB2 EIF3G
2 Decreased viability GR00231-A 10.4 COPB2
3 Decreased viability GR00240-S-1 10.4 ARCN1 COPB2 EIF3G COPA
4 Decreased viability GR00342-S-1 10.4 COPB2
5 Decreased viability GR00342-S-3 10.4 COPB2
6 Decreased viability GR00381-A-1 10.4 EIF3G
7 Decreased viability GR00402-S-2 10.4 ARCN1 COPB2 EIF3G COPA
8 Decreased shRNA abundance GR00251-A-1 10.37 ARCN1 COPA COPB2 DCAF13 EIF3G
9 Decreased shRNA abundance GR00251-A-2 10.37 ARCN1 COPA COPB2 DCAF13 EIF3G
10 Decreased Hepatitis C virus replication GR00180-A-1 10.34 ARCN1 COPA COPB2
11 Decreased Hepatitis C virus replication GR00180-A-2 10.34 ARCN1 COPA COPB2
12 Decreased vesicular stomatitis virus (VSV) infection GR00241-A-1 10.32 ARCN1 COPA COPB2 DCAF13 EIF3G
13 Decreased vesicular stomatitis virus (VSV) infection GR00241-A-2 10.32 ARCN1 COPA COPB2 DCAF13 EIF3G
14 Decreased influenza A virus infection GR00147-A-1 10.29 ARCN1 COPA COPB2
15 Decreased influenza A virus infection GR00147-A-2 10.29 ARCN1 COPA COPB2
16 Decreased cell number GR00098-A-1 10.11 ARCN1 COPA COPB2 EIF3G NEU1
17 Decreased cell number GR00303-A 10.11 COPA COPB2
18 Decreased IL-8 secretion GR00386-A-2 10.01 ARCN1 COPA COPB2 EIF3G IFNB1 NEU1
19 Decreased human parainfluenza virus type 3 (HPIV3) infection GR00241-A-4 9.95 ARCN1 COPA COPB2 DCAF13 EIF3G
20 Decreased lymphocytic choriomeningitis virus (LCMV) infection GR00241-A-3 9.88 ARCN1 COPA COPB2 DCAF13 EIF3G
21 Decreased influenza A/WSN/33 replication GR00195-A-1 9.8 ARCN1 COPA COPB2 EIF3G
22 Decreased influenza A H1N1 (A/WSN/33) virus numbers GR00195-A-2 9.7 COPA COPB2 EIF3G
23 Decreased Salmonella enterica Typhimurium ruffling GR00133-A-5 9.61 ARCN1 COPA COPB2
24 Decreased Salmonella-containing vacuole maturation GR00133-A-2 9.58 ARCN1 COPA COPB2
25 Decreased Salmonella enterica Typhimurium binding GR00133-A-3 9.46 ARCN1 COPA
26 Downregulation of Wnt pathway after Wnt3A stimulation GR00057-A-2 9.33 ARCN1 COPA COPB2
27 G0/1 arrest GR00098-A-2 9.26 ARCN1 COPA COPB2 EIF3G
28 Increased Sindbis virus (SINV) infection GR00310-A-1 8.92 ARCN1 COPA COPB2
29 Increased Sindbis virus (SINV) infection GR00310-A-2 8.92 ARCN1

Drugs & Therapeutics for Parainfluenza Virus Type 3

Drugs for Parainfluenza Virus Type 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glutamic acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
2 Vaccines Phase 1, Phase 2
3 Immunologic Factors Phase 1, Phase 2
4 polysaccharide-K Phase 1
5 Adjuvants, Immunologic Phase 1
6 Anti-Infective Agents Phase 1
7 Protective Agents Phase 1
8 Radiation-Protective Agents Phase 1
9 Anti-Bacterial Agents Phase 1
10 Antibiotics, Antitubercular Phase 1
11 interferons Phase 1
12 Antiviral Agents Phase 1
13 Interferon Inducers Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants Completed NCT00686075 Phase 1, Phase 2
2 An Expanded Phase1/2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Mos. of Age Terminated NCT00508651 Phase 1, Phase 2
3 Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein Completed NCT02564575 Phase 1
4 Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval Completed NCT01254175 Phase 1
5 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children Completed NCT00345670 Phase 1
6 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age Completed NCT00493285 Phase 1
7 Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age Completed NCT00308412 Phase 1
8 Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval Completed NCT01021397 Phase 1 rHPIV3cp45;rHPIV3cp45 placebo
9 A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age Completed NCT00366782 Phase 1
10 Phase 1 Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Recruiting NCT03462004 Phase 1
11 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults Active, not recruiting NCT03392389 Phase 1
12 Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults Completed NCT00111878 MEDI-534

Search NIH Clinical Center for Parainfluenza Virus Type 3

Genetic Tests for Parainfluenza Virus Type 3

Anatomical Context for Parainfluenza Virus Type 3

MalaCards organs/tissues related to Parainfluenza Virus Type 3:

41
Lung, Testes, Bone, T Cells, Bone Marrow, Monocytes, Kidney

Publications for Parainfluenza Virus Type 3

Articles related to Parainfluenza Virus Type 3:

(show top 50) (show all 740)
# Title Authors PMID Year
1
Analysis of Paramyxovirus Transcription and Replication by High-Throughput Sequencing. 38
31189700 2019
2
Profiling of local disease-sparing responses to bovine respiratory syncytial virus in intranasally vaccinated and challenged calves. 38
31146050 2019
3
Molecular Epidemiology of an Outbreak of Human Parainfluenza Virus 3 Among Oncology Patients. 38
31356855 2019
4
The novel caprine parainfluenza virus type 3 showed pathogenicity in Guinea pigs. 38
31163247 2019
5
[Risk factors for calf mortality influence the occurrence of antibodies against the pathogens of enzootic bronchopneumonia]. 38
31212341 2019
6
Mycoplasma bovis and viral agents associated with the development of bovine respiratory disease in adult dairy cows. 38
31232526 2019
7
Respiratory virus associated with surgery in children patients. 38
31208426 2019
8
Detecting respiratory viruses in children with protracted bacterial bronchitis. 38
31047118 2019
9
Isolation of a Divergent Strain of Bovine Parainfluenza Virus Type 3 (BPIV3) Infecting Cattle in China. 38
31146368 2019
10
Proteomics analysis reveals heat shock proteins involved in caprine parainfluenza virus type 3 infection. 38
31101113 2019
11
Virion-Associated Cholesterol Regulates the Infection of Human Parainfluenza Virus Type 3. 38
31096557 2019
12
Epidemiological investigation and phylogenetic analysis of caprine parainfluenza virus type 3 in sheep of China. 38
30770651 2019
13
Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein. 38
30651356 2019
14
Original research article Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells. 38
31022559 2019
15
Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. 38
30940854 2019
16
Emerging views of mitophagy in immunity and autoimmune diseases. 38
30951392 2019
17
Development of a nanoparticle-assisted PCR assay for detection of bovine respiratory syncytial virus. 38
30971257 2019
18
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. 38
30518655 2019
19
Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism. 38
30782664 2019
20
Comparative Evaluation of the Immune Responses in Cattle Mammary Tissues Naturally Infected with Bovine Parainfluenza Virus Type 3 and Bovine Alphaherpesvirus-1. 38
30823555 2019
21
Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs. 38
30550799 2019
22
Involvement of Actin-Regulating Factor Cofilin in the Inclusion Body Formation and RNA Synthesis of Human Parainfluenza Virus Type 3 via Interaction With the Nucleoprotein. 38
30792702 2019
23
Multi-pathogen serological survey of migratory caribou herds: A snapshot in time. 38
31365561 2019
24
New clinical and seasonal evidence of infections by Human Parainfluenzavirus. 38
30143939 2018
25
Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. 38
30420505 2018
26
Metagenomic analysis of viral nucleic acid extraction methods in respiratory clinical samples. 38
30359242 2018
27
A lateral flow dipstick combined with reverse transcription recombinase polymerase amplification for rapid and visual detection of the bovine respirovirus 3. 38
30138696 2018
28
A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3. 38
30071204 2018
29
Cellular microRNA bta-miR-222 suppresses caprine parainfluenza virus type 3 replication via downregulation of interferon regulatory factor 2. 38
30269791 2018
30
Respiratory viruses among children with non-severe community-acquired pneumonia: A prospective cohort study. 38
29908521 2018
31
Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process. 38
29516315 2018
32
Cappariloside A shows antiviral and better anti-inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo. 38
29555588 2018
33
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses. 38
29783756 2018
34
An alanine residue in human parainfluenza virus type 3 phosphoprotein is critical for restricting excessive N0-P interaction and maintaining N solubility. 38
29455063 2018
35
Development of a recombinase polymerase amplification combined with lateral-flow dipstick assay for detection of bovine ephemeral fever virus. 38
29288049 2018
36
Human respiratory syncytial virus: prevalence, viral co-infections and risk factors for lower respiratory tract infections in children under 5 years of age at a general hospital in the Democratic Republic of Congo. 38
29509134 2018
37
Human Parainfluenza Virus Type 3 Infections in Patients with Hematopoietic Stem Cell Transplants: the Mode of Nosocomial Infections and Prognosis. 38
29279454 2018
38
Human Parainfluenza Virus Type 3 Matrix Protein Reduces Viral RNA Synthesis of HPIV3 by Regulating Inclusion Body Formation. 38
29534486 2018
39
Inclusion bodies of human parainfluenza virus type 3 inhibit antiviral stress granule formation by shielding viral RNAs. 38
29518158 2018
40
Innate Immune Response to Viral Infections in Primary Bronchial Epithelial Cells is Modified by the Atopic Status of Asthmatic Patients. 38
29411555 2018
41
Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein. 38
29187536 2018
42
The Sialic Acid Binding Activity of Human Parainfluenza Virus 3 and Mumps Virus Glycoproteins Enhances the Adherence of Group B Streptococci to HEp-2 Cells. 38
30175075 2018
43
Analysis of microRNAs Expression Profiles in Madin-Darby Bovine Kidney Cells Infected With Caprine Parainfluenza Virus Type 3. 38
29651410 2018
44
Screening and Identification of ssDNA Aptamers against HN Protein for Detection of Bovine Parainfluenza Virus Type 3 Antibodies in Serum. 38
30381069 2018
45
DIVA metabolomics: Differentiating vaccination status following viral challenge using metabolomic profiles. 38
29621258 2018
46
Molecular epidemiology and environmental contamination during an outbreak of parainfluenza virus 3 in a haematology ward. 38
28893615 2017
47
Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children. 38
28808938 2017
48
Complete Genome Sequences of Two Human Parainfluenza Virus Type 3 Isolates Collected in Brazil. 38
29217788 2017
49
Development of a blocking ELISA for Caprine parainfluenza virus type 3. 38
28966036 2017
50
Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity. 38
29153777 2017

Variations for Parainfluenza Virus Type 3

Expression for Parainfluenza Virus Type 3

Search GEO for disease gene expression data for Parainfluenza Virus Type 3.

Pathways for Parainfluenza Virus Type 3

GO Terms for Parainfluenza Virus Type 3

Cellular components related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.56 NEU1 COPB2 COPA ARCN1
2 transport vesicle GO:0030133 9.33 COPB2 COPA ARCN1
3 membrane coat GO:0030117 9.32 COPB2 COPA
4 COPI vesicle coat GO:0030126 9.13 COPB2 COPA ARCN1
5 COPI-coated vesicle membrane GO:0030663 8.8 COPB2 COPA ARCN1

Biological processes related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular protein transport GO:0006886 9.5 COPB2 COPA ARCN1
2 vesicle-mediated transport GO:0016192 9.43 COPB2 COPA ARCN1
3 intra-Golgi vesicle-mediated transport GO:0006891 9.16 COPB2 COPA
4 ER to Golgi vesicle-mediated transport GO:0006888 9.13 COPB2 COPA ARCN1
5 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 8.8 COPB2 COPA ARCN1

Sources for Parainfluenza Virus Type 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....